DS-8201: Acceptance of regulatory submission for pre-treated HER2 breast cancer (based on DESTINY-Breast02 trial) in 2021 (AstraZeneca) - Oct 24, 2019 - Q3 2019 Results: Acceptance of regulatory submission for HER2-positive/negative unresectable and/or metastatic breast cancer (based on DESTINY-Breast03, DESTINY-Breast04 trial) in 2021 or later
Regulatory
|